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:   Basic Local Alignment and Search Tool

cDNA

:   complementary DNA
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:   coding sequence
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:   infectious bronchitis virus
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:   leucine‐rich repeat region
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:   open reading frame

RT‐PCR

:   reverse transcriptase PCR

1.. Introduction {#bab1298-sec-0010}
================

Avian infectious bronchitis (AIB) is an acute respiratory disease mainly found in young chickens in commercial poultry farms, causing significant economic losses. The prevalence of infectious bronchitis virus (IBV) is pandemic in a number of countries including India and assumes a variety of clinical forms, ranging from a respiratory disease to infection of the oviduct leading to permanent damage to immature birds and in hens, leading to reduced egg production and a nephropathogenic form of IBV causing acute nephritis, urolithiasis, and mortality [1](#bab1298-bib-0001){ref-type="ref"}. IBV, a causative agent of AIB disease, belongs to the genus *Gammacoronavirus*, subfamily *Coronavirinae*, family *Coronaviridae*, and order *Nidovirales* (International Committee on Taxonomy of Viruses (ICTV) 2011). The genome of IBV is a positive‐sense single‐stranded RNA of about 27.6 kb with the following genomic organization: 5′‐Pol‐S‐3a‐3b‐E‐M‐5a‐5b‐*N*‐untranslated region‐3′ [2](#bab1298-bib-0002){ref-type="ref"}.

All coronaviruses maintain a set of essential genes, including those that encode the polymerase (Pol), spike (S), small membrane (E), membrane (M), and nucleocapsid (N) proteins [3](#bab1298-bib-0003){ref-type="ref"}. The spike gene is translated as a precursor spike S~o~, which is posttranslationally cleaved by host serine protease into S1 and S2 at cleavage sequence motif [4](#bab1298-bib-0004){ref-type="ref"}. The S1 protein is the primary cause of antigenic variations in IBV and contains the serotype‐specific neutralization epitopes, whereas the envelope and membrane proteins are conserved. Antigenic variation among IBV strains is common [1](#bab1298-bib-0001){ref-type="ref"}, [5](#bab1298-bib-0005){ref-type="ref"}, [6](#bab1298-bib-0006){ref-type="ref"}, [7](#bab1298-bib-0007){ref-type="ref"}, [8](#bab1298-bib-0008){ref-type="ref"}; the major prevalent form of IBV in the Indian subcontinent is respiratory and nephropathogenic forms [9](#bab1298-bib-0009){ref-type="ref"}.

The IBV classification of different serotypes is based largely on virus‐neutralization tests, a gold standard test for serodiagnosis of infectious bronchitis in infected birds. Serotype determination is of trivial importance as different serotypes do not always cross protect. Genotyping of IBV strains can also be done by genetic characterization of the spike glycoprotein gene by reverse transcription polymerase chain reaction (RT‐PCR), restriction fragment length polymorphism, and nucleotide sequencing, which for the most part correlates with the viral serotype [10](#bab1298-bib-0010){ref-type="ref"}, [11](#bab1298-bib-0011){ref-type="ref"}. Nucleotide sequencing of the S1 gene is the foremost technique used for differentiation of IBV strains into various genotypes. The emergence of antigenic variants is mostly attributed to variation in the spike gene by recombination [12](#bab1298-bib-0012){ref-type="ref"}, [13](#bab1298-bib-0013){ref-type="ref"} and is investigated by nucleotide sequencing of the S1 portion of the S gene coding for the S1 subunit [14](#bab1298-bib-0014){ref-type="ref"}, [15](#bab1298-bib-0015){ref-type="ref"}, where most of the epitopes to which neutralizing antibodies bind are found [16](#bab1298-bib-0016){ref-type="ref"}. The impact of regular emergence of antigenic variants of the disease and subsequent vaccines used to control varies depending on different geographical locations. Genetic assessment of field isolates of viruses from outbreaks is essential for evaluation of vaccine efficiency on antigenic variants that arise. A critical advantage of sequencing S1 is for comparison and analysis of sequences of unknown field isolates and variants with reference vaccine strains for establishing potential relatedness. IBV vaccines currently used are either live attenuated or killed showing varying degrees of efficacy. At present, many countries only permit live vaccines of the Massachusetts type, such as the H120 strain. Some countries have also licensed other live strain vaccine such as Connecticut, Arkansas, or Delaware 072 in the United States or the 4/91 strain in the United Kingdom. In India, Verma, [17](#bab1298-bib-0017){ref-type="ref"} for the first time reported the prevalence of IBV infections in chickens. The emergence of a nephropathogenic IBV with a novel genotype in India has also been reported [9](#bab1298-bib-0009){ref-type="ref"}. Recently, an outbreak of nephropathogenic AIB in broiler flocks was reported in the Chhattisgarh region of India [18](#bab1298-bib-0018){ref-type="ref"}.

In this study, we amplified and sequenced the spike gene of the live infectious bronchitis attenuated vaccine virus, which is routinely used in India. Bioinformatics was applied to evaluation of the spike gene for characterization and spike gene\'s relatedness with previously reported Indian IBV isolates.

2.. Materials and Methods {#bab1298-sec-0020}
=========================

2.1.. Virus {#bab1298-sec-0030}
-----------

Viral RNA was isolated from the AIB vaccine, living bp vet (Mass type strain; Ventri Biologicals, Pune, India). A virus sample was obtained in a freeze‐dried form that was dissolved in 1 mL normal saline; 0.1 mL of the inoculum was inoculated in five 10‐day‐old specific pathogen free chicken eggs (Venky\'s Hatcheries, Pune, India), and the eggs were candled daily for 96 H. The allantoic fluid was collected and centrifuged at 1700 g for 10 Min at room temperature, and a supernatant was stored at --20°C until use.

2.2.. RNA isolation and RT‐PCR {#bab1298-sec-0040}
------------------------------

Total RNA from the infected allantoic fluid was extracted by a Trizol reagent (Sigma, St. Louis, MO, USA) as per the manufacturer\'s protocol. The extracted RNA was first reverse‐transcribed with gene‐specific primers and a thermoscript RT kit (Invitrogen, Carlsbad, CA, USA) to synthesize the first‐strand cDNA. Synthesized cDNA was screened for the presence of IBV genome by a polymerase chain reaction (PCR) with a set of primers specific to the spike gene of IBV. Primers were used to amplify the complete coding sequence (CDS) of the *S gene* including forward 5′‐CCC**GAATTC**ATGTTGGTAACACCTCTTTTACTAG‐3 (*Eco*RI) (nucleotide position 20374‐20398) and reverse primer 5′‐GCG**GAGCTC**TTAAACAGACTTTTTAGGTC‐3′ (*Sac*I) (nucleotide position 20843--23862), designed from Massachusetts M41 serotype (FJ904723). PCR amplification was carried out using Pfu DNA polymerase (Thermo Scientific, Waltham, MA, USA) with the following cycling conditions: 94°C for 5 Min followed by 30 cycles of 94°C for 1 Min, 60°C for 1 Min, 72°C for 1.5 Min, with a final extension of 72°C for 10 Min. The PCR‐amplified gene fragment was cloned with a cloning vector CloneJET^TM^ (Thermo Scientific). The size of amplicon was 3489 bp. The PCR product was visualized by agar gel electrophoresis and confirmed by restriction enzyme digestion and sequencing.

2.3.. Sequence and phylogenetic analysis {#bab1298-sec-0050}
----------------------------------------

Sequences were analyzed using Chromas Lite 2.1.1. The nucleotide sequence of the S gene of Indian IBV vaccine strain was assembled and aligned by clustalW [19](#bab1298-bib-0019){ref-type="ref"} after Basic Local Alignment and Search Tool (BLAST) search with published IBV sequences deposited to the GenBank database. Sequence identities by BLAST analysis were included in the alignment and phylogenetic tree construction. The multiple sequence alignments and phylogenetic tree construction with the neighbor joining method were performed using MEGA version 5 [20](#bab1298-bib-0020){ref-type="ref"}. The bootstrap values were determined from 1,000 replicates of the original data. Phylogenetic analysis of nucleic acid and deduced amino acid sequences was carried out with the neighbor joining method using the Jukes--Cantor model and pairwise deletion. The S gene sequences from the GenBank database, which were used for comparison or phylogenetic analysis in this study, are enlisted in Tables [1](#bab1298-tbl-0001){ref-type="table"} and [2](#bab1298-tbl-0002){ref-type="table"}.

###### 

Selected IBV strains used in this study

  Strain                  Year  Country            NCBI accession number
  ---------------------- ------ ----------------- -----------------------
  H120                    1989  The Netherlands           M21970
  H120                    1960  The Netherlands          GU393335
  H120                    2009  Taiwan                   EU822341
  H120                    1960  The Netherlands           FJ88835
  M41                     2009  India                    GQ219712
  M41                     2006  United States            FJ904713
  M41                     1972  United States            FJ904721
  M41                     2006  United States            DQ834384
  M41                     1965  United States            FJ904720
  Beaudette               2005  Singapore                DQ001334
  Beaudette               2005  Singapore                DQ001336
  Beaudette               2005  Singapore                DQ001340
  Conn46                  1991  United States            FJ904719
  Conn46                  1983  United States            FJ904718
  Conn46                  1972  United States            FJ904717
  Ark‐dpi                 2009  United States            EU418976
  JMK                     1964  United States            GU393338
  Holte                   1954  United States            GU393336
  3071/03                 2004  Taiwan                   AY606319
  6/82                    1993  United Kingdom            X04723
  CK/CH/LSD/05I           2008  China                    EU637854
  CK/CH/LDL971/97         2004  China                    DQ068701
  CK/CH/LGD/120724        2012  China                    KC119407
  CK/CH/LZJ/111113        2011  China                    JX195176
  4/91                    1998  United Kingdom           AF093794
  4/91                    2011  United Kingdom           JN192154
  Egypt/F/03              2003  Egypt                    DQ487085
  Nephropathogenic HBC    2006  China                    DQ973112
  Nephropathogenic        2006  China                    DQ973114
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###### 

Selected Indian IBV isolates used in this study

  Isolate                 Year       Region/strain       NCBI accession number
  ---------------------- ------ ----------------------- -----------------------
  IBS1_UP_09_15           2009   Uttar Pradesh, India          GU967401
  IBS1_AP_09_15           2008   Andhra Pradesh, India         GU967405
  IBS1_UKND_08_14         2008       Massachusetts             GU967392
  India‐744‐AD‐04         2004       Massachusetts             HQ291840
  India‐764‐AD‐04         2004       Massachusetts             HQ291841
  India‐627‐AD‐02         2002       Massachusetts             HQ291842
  India‐16‐V‐AD‐07        2007       Massachusetts             HM179146
  India/LKW/IVRI/56/08    2008       Massachusetts             HM163471
  PDRC/PUNE/India/9/99    2004     Nephropathogenic            AY091551
  India/NMK/72/IVRI/10    2010          Namkkal                HM748585
  India M41               2009       Massachusetts             GQ219712
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2.4.. Bioinformatics analysis {#bab1298-sec-0060}
-----------------------------

*N*‐Glycosylation sites were predicted by using the facility available at <http://www.cbs.dtu.dk/services/NetNGlyc>. Leucine‐rich repeat regions (LRR) were determined by LRRfinder, which is available at <http://www.lrrfinder.com/result.php>.

3.. Results {#bab1298-sec-0070}
===========

3.1.. PCR amplification and sequencing of the spike gene {#bab1298-sec-0080}
--------------------------------------------------------

The spike gene was amplified using a cDNA template prepared from isolated RNA of commercial IBV vaccine available in India. On agarose gel electrophoresis, a positive amplification of 3.4‐kb band was seen (Fig. [1](#bab1298-fig-0001){ref-type="fig"}), which was gel eluted and cloned. The resulting full‐length CDS of spike gene was submitted to the GenBank (accession number KF188436).

![PCR amplification product of the spike gene in 1.2% agarose.](BAB-63-106-g001){#bab1298-fig-0001}

3.2.. Phylogenetic analysis and percent identity of spike gene sequences {#bab1298-sec-0090}
------------------------------------------------------------------------

The partial CDS of the *S gene* was compared with relevant available IBV sequences in the GenBank (Tables [1](#bab1298-tbl-0001){ref-type="table"} and [2](#bab1298-tbl-0002){ref-type="table"}). Phylogenetic analyses of the Indian vaccine strain of IBV were carried out based on the partial CDS of the spike gene. Published IBV sequences of Massachusetts type, M41, H120, Baudette, 4/91, Conn46, Ark‐dpi, JMK, Holte, 3071/03, 6/82, CK/CH, 4/91, Egypt/F/03, and nephropathogenic and Indian IBV isolates available in the GenBank were used to determine phylogenetic characteristics and molecular epidemiology of the Indian vaccine strain. No complete spike gene sequences of the Indian IBV isolates genotype were available in the GenBank; therefore partial CDS of KF188436 and other previously reported Indian isolates were analyzed. The phylogenetic analysis based on the partial S1 gene sequence of the Indian vaccine strain showed that it belongs to the H120 strain of IBV, which is a type of Massachusetts strain routinely used as a vaccine strain worldwide (Fig. [2](#bab1298-fig-0002){ref-type="fig"}). Some Indian isolates were clustered together to form a distinct cluster, whereas AY091551 and HM748585 were clustered with the Chinese nephropathological strain (DQ973112 and DQ973114) and 6/41 of UK (AF093794 and JN192154), respectively. Interestingly, one Indian isolate HM163471 was clustered with the Egyptian isolate DQ487085, which is a nephropathogenic strain of AIB virus found in Egypt.

![Phylogenetic analysis of the partial CDS of the S gene of IBV obtained from the Indian vaccine strain at the nucleotide level.](BAB-63-106-g002){#bab1298-fig-0002}

To determine the relatedness among Indian isolates, a comparative analysis of the nucleotide sequences of the spike gene (KF188436.1) with previously reported sequences of the *S gene* from Indian isolates was carried out. A higher nucleotide sequence homology was shown by Indian isolates GU967405, GQ219712, and GU967392 with KF188436, which is around 98.4%, 99.0%, and 99.0%, respectively. The isolates GU967387, HQ291841, HQ291842, and HM179146 showed around 90.6%--93.7% nucleotide sequence homology to KF188436. The lowest sequence homology to KF188436 was shown by isolates HM748585 and HQ291840, which was about 71.8% and 87.7%, respectively. The nucleotide sequence divergence of reported Indian isolates from KF188438 was 0.1%--3.5% with the exception of HM748585. The Spike gene of infectious bronchitis harbors recombinational hotspots; no crossover was observed between the vaccine strain and field isolates.

The deduced amino acid sequences of the spike glycoprotein from the Indian IBV vaccine strain and previously reported Indian isolates exhibited 71.4%--96.9% homology. Indian isolates GQ219712 (96.9%), GU967392 (96.6%), GU967401 (96%), and GU967405 (94.9%) showed the highest percent homology with KF188436, whereas isolates HQ291841 (93.1%) and HQ291842 (93.9%) showed intermediate homology. The lowest percent homology to the vaccine strain was shown by Indian isolates HM163471 (89.7%), HM179146 (89.7%), HM748585 (71.4%), and HQ291840 (71.4%).

3.3.. Analysis of the spike protein cleavage site {#bab1298-sec-0100}
-------------------------------------------------

A deduced amino acid sequence of Indian isolates has shown a cleavage sequence motif Arg--Arg--Phe--Arg--Arg in a sequenced KF188436 H120 vaccine strain and other reported Indian isolates at the amino acid position 533 [21](#bab1298-bib-0021){ref-type="ref"} (Table [3](#bab1298-tbl-0003){ref-type="table"}).

###### 

Cleavage site motif in Indian isolates of IBV

  Indian isolate   Type               Cleavage site sequence motif
  ---------------- ------------------ ---------------------------------
  KF188436         H120               533 Arg--Arg--Phe--Arg--Arg 537
  GQ219712         Massachusetts 41   533 Arg--Arg--Phe--Arg--Arg 537
  GU967392         Massachusetts 41   533 Arg--Arg--Phe--Arg--Arg 537
  GU967401         Massachusetts 41   533 Arg--Arg--Phe--Arg--Arg 537
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3.4.. Prediction of potential *N*‐glycosylation sites {#bab1298-sec-0110}
-----------------------------------------------------

*N*‐Glycosylation sites were predicted based on the presence of conserved motif Asn--Xaa--Ser/Thr in a sequence where an Asn residue is *N*‐glycosylated. Twenty‐six *N*‐glycosylation sites were found in the KF188436 strain. In other Indian isolates, most of the sites were found to be conserved with some exception (Table [4](#bab1298-tbl-0004){ref-type="table"})

###### 

Distribution of *N*‐glycosylation in the S1 sequence of the spike gene (up to cleavage motif)

              Position of *N*‐glycosylation sites (amino acid position)                                                                              
  ---------- ----------------------------------------------------------- ---- ---- ----- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  KF188436                               ++                               \+   ++   +++   ++   \+   ++   \+   \+   \+   \+   \+   \+   \+   \+   \+   ++
  GU967392                                                                                                                        ×                  
  HM163471                                                                                                              ×                            
  HM179146                                                                                          ×                                                
  HQ291841                                                                           ×              ×                                  ×             
  HQ291842                                                                                                                             ×             

Cleavage site at the amino acid position = 53. + indicates the presence of *N*‐glycosylation.

× indicates the absence *N*‐glycosylation.
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3.5.. Determination of leucine‐rich repeat regions and signal peptide {#bab1298-sec-0120}
---------------------------------------------------------------------

The LRR region of 84 amino acids in length was found in the infectious bronchitis vaccine strain KF188436 starting at position 1079 (LEKLSILKTYI). A signal peptide MLVTPLLLVTLLCALCSA was found in the vaccine strain H120 with a signal peptide probability of 0.729.

4.. Discussion {#bab1298-sec-0130}
==============

In this study, we carried out propagation, amplification, sequencing, and bioinformatic analysis of the complete spike gene from the Indian vaccine strain, routinely used for vaccination of poultry birds. Sequencing result showed that the open reading frame (ORF) of the Indian vaccine strain was 3,489 bp with a cleavage site for spike located at 1,596 bp, which is equivalent to 532 amino acids. This is the first report on a complete CDS spike gene of an Indian IBV vaccine strain. Universal primers are available for cloning and sequencing of the spike gene; self‐designed primers were used in this study. In phylogenetic analysis, the spike sequence was clustered together with the H120 vaccine strain of IBV. The H120 strain is a live attenuated vaccine strain of Massachusetts (Mass) serotype, originally prepared after 120th serial passage of strain H, isolated from embryonated chicken eggs in the year 1956 in the Netherlands [22](#bab1298-bib-0022){ref-type="ref"}. The H120 strain is considered to be one of the safest vaccine strains and is used worldwide as a primary vaccine in broilers, breeders, and future layers.

It has been reported that the differences in S1 probably contribute to failure of cross protection. However, common epitopes exist between isolates, which are of importance in cross‐immunity; some of these are likely to be on proteins other than S1. The degree of cross protection induced by UK/6/82 against homologous and heterologous IBV isolates diminished as the similarity of the S1 proteins diminished [12](#bab1298-bib-0012){ref-type="ref"}. In a study involving vaccination of birds with single vaccination with 6/82 failed to protect all chicks against isolates with extremely similar (\>98% identity) *S1* sequences, indicating that a slight change in the S1 sequence may have led to the failure of vaccine [12](#bab1298-bib-0012){ref-type="ref"}. The Indian IBV vaccine strain H120 showed 71.4%--96.9% homology at an amino acid level and 71.8--99% homology at a nucleotide level. So the degree of protection may be higher with homologous genotype compared to heterologous ones. It is presumed that the degree of cross protection between different serotypes is less, but some strains of the IBV viruses do induce cross protection against other serotypes and are known to as protectotypes. The H120 strain of IBV is a well‐known protectotype and has been extensively used for vaccination. To overcome the problem associated with different serotypes and genotypes, it has been reported that vaccinating with two different types of IBV vaccine can provide broad protection against different IBV types [5](#bab1298-bib-0005){ref-type="ref"}. A different combination of protectotypes can be tested to achieve a high level of cross protection and to overcome a problem of vaccination failure. The study involving the Indian vaccine strain Ma41 with 94.8%--98.8% homology to field isolates showed good cross protection [23](#bab1298-bib-0023){ref-type="ref"}. Other than spike, enhancement of humoral immunity against IBV by a bicistronic DNA vaccine plasmid encoding nucleocapsid protein and interleukin‐2 has shown up to 80% of protection [24](#bab1298-bib-0024){ref-type="ref"}.

Twenty‐six *N*‐glycosylation sites were found in the vaccine strain, out of which 17 sites are present in the S1 region, which is an ectodomain of the spike gene. The reported Indian IBV isolates have lost some of the *N*‐glycosylation sites (Table [4](#bab1298-tbl-0004){ref-type="table"}). As *N*‐glycosylation is a regular event in posttranslational modification of the protein, changes in a glycosylation pattern can modulate antigenic properties of the protein as antibodies raised against glycoprotein may be specific for a carbohydrate moiety of the glycoprotein [25](#bab1298-bib-0025){ref-type="ref"}. Diversification of the glycosylation pattern may influence a survival pattern and a transmission property of virus, in lactate dehydrogenase elevating virus, a member of the *Coronaviridae* family; determinants of changes in virulence and cellular tropism of virus are loss or acquisition of *N*‐glycosylation sites of the protein [26](#bab1298-bib-0026){ref-type="ref"}.

The precursor spike glycoprotein (S) of IBV is posttranslationally cleaved by a host serine protease at the cleavage site motif into two subunits (S1 and S2). The cleavage recognition site consists of five basic amino acid residues, and variation in a sequence and composition does not correlate with serotype or pathogenicity of IBV as different serotypes as well as attenuated and pathogenic isolates contain the same cleavage recognition site that correlate with viruses of different geographic regions [21](#bab1298-bib-0021){ref-type="ref"}. The Indian vaccine strain KF188436, which belongs to Massachusetts (Mass) serotype, is shown to have an Arg--Arg--Phe--Arg--Arg cleavage recognition site, which correlates with isolates THA241251, THA280252, THA290252, and THA320352 of Thailand [21](#bab1298-bib-0021){ref-type="ref"}; FJ888351, GQ154655, and FJ888351 of China; and GU393335 of the United States. It shows that the H120 strain mostly has a RRFRR cleavage recognition site. LRR is a structural motif of protein like alpha/beta horseshoe fold and is responsible for protein==protein interactions [27](#bab1298-bib-0027){ref-type="ref"}, [28](#bab1298-bib-0028){ref-type="ref"}. In KF188436, LRR is present at position 1079 that is a part of the S2 protein and may be responsible for an interaction with other proteins of IBV.

In conclusion, the results of the current study show that the current vaccine strain, which is routinely used for field vaccination of poultry birds, belongs to the H120 strain. The percent identity of the spike gene sequence of the H120 strain with the Indian isolates shows varying degrees of similarity. The vaccine strain used is sufficiently protective based on a similarity study but further *in vivo* cross protection studies should be carried out to check the cross protection potential of the current vaccine against field isolates.
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